Loading…

Reduction in parathyroid adenomas by cinacalcet therapy in patients with primary hyperparathyroidism

Introduction Cinacalcet is a calcimimetic that modulates the functions of calcium-sensing receptor and is currently used to treat patients with primary hyperparathyroidism (PHPT). Although it was reported that cinacalcet treatment reduced the size of hyperplastic parathyroid glands in patients with...

Full description

Saved in:
Bibliographic Details
Published in:Journal of bone and mineral metabolism 2021-07, Vol.39 (4), p.583-588
Main Authors: Minezaki, Midori, Takashi, Yuichi, Ochi, Kentaro, Mitsuoka, Ryo, Yamao, Yuka, Kudo, Tadachika, Kawanami, Daiji, Kobayashi, Kunihisa, Abe, Ichiro
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Cinacalcet is a calcimimetic that modulates the functions of calcium-sensing receptor and is currently used to treat patients with primary hyperparathyroidism (PHPT). Although it was reported that cinacalcet treatment reduced the size of hyperplastic parathyroid glands in patients with secondary hyperparathyroidism, whether or not cinacalcet treatment can reduce the size of parathyroid adenomas in patients with PHPT has been unknown. Materials and methods We recruited nine (male: one, female: eight) patients with PHPT due to parathyroid adenomas who did not undergo parathyroidectomy. Cinacalcet was administered at a dose of 50 mg/day, and we evaluated the size of parathyroid adenomas (width × thickness) (mm 2 ) using ultrasonography before and after 6 months of cinacalcet treatment. Results The mean age of the subjects was 58.1 ± 7.2 years old, and the mean serum intact parathyroid hormone (PTH) concentration was 134.8 ± 8.7 pg/ml. All participants showed hypercalcemia and osteopenia. After 6 months, the mean size of parathyroid adenomas was significantly decreased (baseline: 73.8 ± 33.4 mm 2 vs. after 6 months: 52.5 ± 25.0 mm 2 , p  = 0.045). Thus, 6-month cinacalcet treatment induced a 29% size reduction in parathyroid adenomas. Furthermore, the serum intact PTH concentration before cinacalcet treatment was positively correlated with the reduction in the size of parathyroid adenomas. Conclusion The present study revealed that cinacalcet treatment reduces the size of parathyroid adenomas in patients with PHPT. The accumulation of more PHPT cases with cinacalcet therapy is required to confirm this finding.
ISSN:0914-8779
1435-5604
DOI:10.1007/s00774-020-01190-2